Register Login

AXSOME THERAPEUTICS, INC. (AXSM)

(80% Positive) AXSOME THERAPEUTICS, INC. (AXSM) Announces Enrollment Update for agitation associated Due to Pandemic-Related Challenges, Patient Enrollment Issues, Regulatory Process, Safety Review, Efficacy Assessment

Full text
Register to leave comments
  • News bot April 30, 2026, 9:19 p.m.

    📋 AXSOME THERAPEUTICS, INC. (AXSM) - Clinical Trial Update

    Filing Date: 2026-04-30

    Accepted: 2026-04-30 17:19:05

    Event Type: Clinical Trial Update

    Event Details:

    AXSOME THERAPEUTICS, INC. (AXSM) Announces Clinical Trial Update AXSOME THERAPEUTICS, INC. (AXSM) provided an update on its clinical development programs. Clinical Development Highlights:
    • Drug Program: agitation associated, Agitation Associated
    • Diseases/Conditions: Dementia, dementia
    • Collaboration: FDA

    🔬 Clinical Development Pipeline (AXSOME THERAPEUTICS, INC.):

    Product Type Development Stage Therapeutic Area Source
    AXS-05 (dextromethorphan-bupropion) DRUG Phase PHASE3 Agitation in Patients With Dementia of the Alzheimer's Type ClinicalTrials.gov
    No treatment OTHER Preclinical Narcolepsy ClinicalTrials.gov
    AXS-05 DRUG Phase PHASE4 Major Depressive Disorder ClinicalTrials.gov
    Placebo DRUG Phase PHASE3 Major Depressive Disorder With Excessive Daytime Sleepiness Symptoms ClinicalTrials.gov
    Solriamfetol 150 MG DRUG Phase PHASE3 Major Depressive Disorder With Excessive Daytime Sleepiness Symptoms ClinicalTrials.gov
    AXS-14 (Esreboxetine) DRUG Phase PHASE3 Fibromyalgia ClinicalTrials.gov
    Solriamfetol 75mg, 150 mg, or 300 mg DRUG Phase PHASE3 Binge-Eating Disorder ClinicalTrials.gov
    Solriamfetol 300 mg DRUG Phase PHASE3 Excessive Sleepiness ClinicalTrials.gov
    Other prescription wake-promoting medications or stimulants DRUG Preclinical Narcolepsy ClinicalTrials.gov
    Sunosi (solriamfetol) DRUG Preclinical Narcolepsy ClinicalTrials.gov
    Bupropion DRUG Phase PHASE4 Major Depressive Disorder ClinicalTrials.gov
    Solriamfetol DRUG Phase PHASE2 Multiple Sclerosis ClinicalTrials.gov
    Monitoring OTHER Phase PHASE4 Insomnia ClinicalTrials.gov
    Cognitive Behavioral Therapy for Insomnia (CBT-I) BEHAVIORAL Phase PHASE4 Insomnia ClinicalTrials.gov
    Solriamfetol 75 MG DRUG Phase PHASE4 Insomnia ClinicalTrials.gov
    AXS-07 (meloxicam-rizatriptan) DRUG Phase PHASE3 Migraine ClinicalTrials.gov
    AXS-12 (reboxetine) DRUG Phase PHASE3 Narcolepsy ClinicalTrials.gov
    Solriamfetol 150 mg Oral Tablet DRUG Phase PHASE1 Narcolepsy ClinicalTrials.gov
    Bupropion SR DRUG Phase PHASE2 Major Depressive Disorder ClinicalTrials.gov
    Solriamfetol Oral Tablet DRUG Phase PHASE4 Excessive Sleepiness ClinicalTrials.gov
    AXS-07 (MoSEIC meloxicam and rizatriptan) DRUG Phase PHASE3 Migraine ClinicalTrials.gov
    AXS-07 DRUG Phase PHASE3 Migraine ClinicalTrials.gov
    AXS-05 (dextromethorphan and bupropion) oral tablets DRUG Phase PHASE3 Major Depressive Disorder ClinicalTrials.gov
    Rizatriptan DRUG Phase PHASE3 Migraine ClinicalTrials.gov
    Meloxicam DRUG Phase PHASE3 Migraine ClinicalTrials.gov
    AXS-02 DRUG Phase PHASE3 Osteoarthritis, Knee ClinicalTrials.gov
    AXS-02 (oral zoledronate) DRUG Phase PHASE3 Complex Regional Pain Syndrome ClinicalTrials.gov

    💼 Business Developments:

    • Partnership
    • Acquisition: Not available
    • Licensing
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: AXSOME THERAPEUTICS, INC.
    • Ticker Symbol: AXSM

Search

News categories